Browse By: CountryιCategoryιPublisherιTag
Home  »  Pharmaceutical

Pharmaceutical Market Research Reports

Prev 1 2 3 4 5 6 7 8 9 10 Next
Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific
GBI Research, the leading business intelligence provider, has released its latest research, “Critical Care Market to 2019 - Growth from Factor Concentrates, New Indications and Increasing Demand for Albumin in Asia-Pacific”. The report provides in-depth analysis of the drivers and barriers that affect the global critical care market. The report has been compiled using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.  The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates,...
Published Date: May 2013
Published By: GBI Research

Price: $3500
Analysis of the perfume&cosmetic retail market in Russia - in English and Russian languages
Purpose of this report was to analyse the perfume & cosmetic retail industry in Russia. Please pay attention: Benefits of buying the report: The report provides information, which gives very good understanding of trends and dynamics of the market in Russia. The report forms a view with respect to development of the market. This view and forecast can be used in running scenario analysis to build financial models, investment analysis and strategy formulation. Main competitors were analyzed during the course of the report. You will get clear understanding of l...
Published Date: May 2013
Published By: Euroresearch & Consulting

Price: $1850
Russian pharma industry in details - in English and Russian languages
Purpose of this report was to analyze Russian of pharma. Please pay attention: Benefits of buying the report: The report included large volume of information on Russian pharma industry. The report is ready to be used for presentations, research reports and strategies. The report could also be used in preparation of marketing materials. The focus of the report – development of pharma market in Russia. The report contains information on pharma clusters in regions of Russia. The report has information on regulation of the pharma industry in Russia. In one report you will get...
Published Date: May 2013
Published By: Euroresearch & Consulting

Price: $3750
Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) potentially supplemented by approvals for Alzheimers disease
GBI Research’s report: Immunoglobulin Market to 2019 provides in-depth analysis of the global immunoglobulin market. The report analyzes the markets for immunoglobulin products in the US, the top five European countries (the UK, Germany, France, Italy and Spain) and Japan. The revenue and annual cost of therapy are forecast for the key geographies and in seven key therapeutic segments, along with epidemiology data, until 2019.  The seven key therapeutic segments are Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Multifocal Motor Neuropathy (MMN), Guillain-Barré Syndrome (GBS), Myas...
Published Date: May 2013
Published By: GBI Research

Price: $3500
Discovery Stage Partnering Terms and Agreements in Pharma and Biotech
The Discovery Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter discovery stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Understanding the flexibility of a prospective partner’s negotiated deals terms provides criti...
Published Date: May 2013
Published By: Current Partnering

Price: $2995
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech
The Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the preclinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides a detailed understanding and analysis of how and why companies enter preclinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 
Published Date: May 2013
Published By: Current Partnering

Price: $2995
Antibiotics Partnering Terms and Agreements
The Antibiotics Partnering Agreements report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in antibiotics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Antibiotics partnering contract documents Top antibiotics deals by value The Antibiotics Partnering Terms and Agreements report provides an understanding and access t...
Published Date: May 2013
Published By: Current Partnering

Price: $1795
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
Provides comprehensive understanding and unprecedented access to discovery, preclinical and clinical stage partnering agreements entered into by the worlds leading biopharma companies  The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why ...
Published Date: May 2013
Published By: Current Partnering

Price: $4995
Antibiotics Markets in China
China's demand for antibiotics has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Autoimmune Drugs Markets in China
China's demand for autoimmune drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Blood Disease Treatment Drugs Markets in China
China's demand for blood treatment disease drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Hypertension Treatment Drugs Markets in China
China's demand for hypertension treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Mental Illness Treatment Drugs Markets in China
China's demand for mental illness treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Anti-Obesity Drugs Markets in China
China's demand for anti-obesity drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Osteoporosis Treatment Drugs Markets in China
China's demand for osteoporosis treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Anti-Tumor Drugs Markets in China
China's demand for anti-tumor drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Lymphoma Treatment Drugs Markets in China
China's demand for lymphoma treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Central Nervous System Disorder Drugs Markets in China
China's demand for central nervous system disorder drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Monoclonal Antibody Markets in China
China's demand for monoclonal antibody has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Smoking Cessation Aids Markets in China
China's demand for smoking cessation aids has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Disinfectants Markets in China
China's demand for disinfectants has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Pneumonia Treatment Drugs Markets in China
China's demand for pneumonia treatment drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: May 2013
Published By: Asia Market Information & Development Company

Price: $2000
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q1 2013
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q1 2013 Summary GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals Q1 2013 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and v...
Published Date: Apr 2013
Published By: GlobalData

Price: $1500
Generic and innovative drugs market in CIS countries 2013. Russia, Ukraine and Kazakhstan
Keep current with the changing CIS generic and innovative drug segments. Survey conditions and track market development in Russian Ukraine and Kazakhstan to 2015. Generic and innovative drug segments in CIS countries have played a huge role in \ supporting the pharmaceutical industry. Meanwhile, the effects of programmes such as Russias Pharma 2020, Kazakhstans GMP initiative and Ukraines updated reimbursement structure are visible in the marketplace.  How will issues like these influence market development in the next few years? How will they change pricing structures and reimbursement schemes? What are the rules regarding data exclusivity periods and drug patent viability?
Published Date: Apr 2013
Published By: PMR

Price: $2800
Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players
Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players Summary GBI Research, the leading business intelligence provider, has released its latest research “Japan Pharmaceutical Market Outlook Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players”. Japan’s pharmaceutical industry is the sec...
Published Date: Apr 2013
Published By: GBI Research

Price: $3500
Anorexia Nervosa Global Clinical Trials Review, H1, 2013
Anorexia Nervosa Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Anorexia Nervosa Global Clinical Trials Review, H1, 2013" provides data on the Anorexia Nervosa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Anorexia Nervosa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs fo...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Delirium Global Clinical Trials Review, H1, 2013
Delirium Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Delirium Global Clinical Trials Review, H1, 2013" provides data on the Delirium clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Delirium. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Delirium. This report...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Diverticulitis Global Clinical Trials Review, H1, 2013
Diverticulitis Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Diverticulitis Global Clinical Trials Review, H1, 2013" provides data on the Diverticulitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diverticulitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treati...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Dyskinesia Global Clinical Trials Review, H1, 2013
Dyskinesia Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyskinesia. T...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Dystonia Global Clinical Trials Review, H1, 2013
Dystonia Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Dystonia Global Clinical Trials Review, H1, 2013" provides data on the Dystonia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dystonia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dystonia. This report...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Radiculopathy Global Clinical Trials Review, H1, 2013
Radiculopathy Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, Radiculopathy Global Clinical Trials Review, H1, 2013" provides data on the Radiculopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Radiculopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating R...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
PharmaSphere: Early-Stage Technology Transfer Collaborations - Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry
PharmaSphere: Early-Stage Technology Transfer Collaborations Enabling Platform Technologies & Deal Synergies between Academia and the Pharmaceutical Industry Summary The PharmaSphere, Early-Stage Technology Transfer Collaborations Report provides a cross-section of major licensing deals between mid to large-sized pharmaceutical companies and academic and nonprofit research institutions. This report examines the terms, platform technologies, and deal rationale of 25 pharma-academic alliances from 20122013. GlobalDatas Industry Dynamics team of analysts discusses the significant macro-environment drivers which are leading to an increase in research partn...
Published Date: Apr 2013
Published By: GlobalData

Price: $2995
Prescription Drugs Markets in China
China's demand for prescription drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: Apr 2013
Published By: Asia Market Information & Development Company

Price: $2000
Incretion Drugs Markets in China
China's demand for incretion drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: Apr 2013
Published By: Asia Market Information & Development Company

Price: $2000
Pediatric Drugs Markets in China
China's demand for pediatric drugs has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: Apr 2013
Published By: Asia Market Information & Development Company

Price: $2000
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment
ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment GBI Research, the leading business intelligence provider, has released its latest research: “ADHD Therapeutics Market to 2018 - New Diagnostic Parameters for Adult ADHD Offer Hope for Higher Rates of Treatment”. The report provides insights into the up-and-coming trends of the ADHD market in seven major markets: the US, the top five European countries (France, Germany, Italy, Spain and the UK) and Japan. 
Published Date: Apr 2013
Published By: GBI Research

Price: $3500
China Vitamin Industry Report, 2012-2015
As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of the total output in the same period; moreover, it holds a leading position worldwide in both production technology and market share of vitamin C, vitamin E, vitamin A, vitamin B2, etc.. However, due to the impact of the economic downturn in Europe and the United States, China’s future vitamin market will face grim situation, especially exports even see further decline. Vitamin output in 2013-2015 is expected to be around 220,000-280,000 tons, of which, export volume will make up 75%-80%.  ...
Published Date: Apr 2013
Published By: Research In China

Price: $1800
Dyslexia Global Clinical Trials Review, H1, 2013
Dyslexia Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Dyslexia Global Clinical Trials Review, H1, 2013" provides data on the Dyslexia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Dyslexia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Dyslexia. This report is built using data and information sourced from proprietary d...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013
Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Lennox-Gastaut Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Lennox-Gastaut Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Lennox-Gastaut Syndrome....
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Tardive Dyskinesia Global Clinical Trials Review, H1, 2013
Tardive Dyskinesia Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Tardive Dyskinesia Global Clinical Trials Review, H1, 2013" provides data on the Tardive Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tardive Dyskinesia. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Tardive Dyskinesia. This report is built usi...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Bronchospasm Global Clinical Trials Review, H1, 2013
Bronchospasm Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Bronchospasm Global Clinical Trials Review, H1, 2013" provides data on the Bronchospasm clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bronchospasm. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bronchospasm. This report is built using data and information source...
Published Date: Apr 2013
Published By: GlobalData

Price: $2500
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals
Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals Summary GlobalData's Partnerships, Licensing, Investments and M&A Deals and Trends for March 2013 in Pharmaceuticals report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in March 2013. The report portrays detailed comparative data on the number o...
Published Date: Apr 2013
Published By: GlobalData

Price: $1000
Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.    The report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.  Understanding the flexibility of a prospective partner’s negotiated deals terms provid...
Published Date: Apr 2013
Published By: Current Partnering

Price: $2995
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
Adult and Adolescent Vaccines Market to 2018 - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth Adult and Adolescent Vaccines Market to 2018. The report provides insights into the vaccines in the adult and adolescent vaccines market, including market forecasts up to 2018. It provides an in-depth analysis of the vaccines for the adult and adolescent market, as well as insights into the adult and adolescent vaccines market’s Research and Development (R&D) pipeline. The report provides in-depth analysis of the unmet needs, drivers and barriers that affect the...
Published Date: Apr 2013
Published By: GBI Research

Price: $3500
Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players
Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players Oncology Therapeutics Market in India to 2018 - Introduction of Market-Based Pricing to Fuel Price Wars and Intense Competition Among Domestic and Multinational Players’, which provides in-depth analysis of the key therapeutic indications of oncology, breast cancer, colorectal cancer, prostate cancer, lung cancer and Non-Hodgkin’s Lymphoma (NHL), with forecasts until 2018. It also looks at treatment usage patterns and includes insights into the oncology R&D pip...
Published Date: Apr 2013
Published By: GBI Research

Price: $3500
Insulin Aspart - Comprehensive patent search
Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait.  Used by the worlds leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information. Pipeline Developer features: 
Published Date: Apr 2013
Published By: GenericsWeb

Price: $10500
Cold, Flu and Allergy Remedies - US - April 2013
While sales of OTC cold, flu, and allergy products have increased, the category faces several challenges, such as sales of private label brands as well as natural alternatives eroding market share of OTC products. Some questions answered in this report include: Across the board in OTC remedies, there has been an increase in private label sales—both as a reaction to Johnson & Johnson recalls and as a cost saving measure in light of the recession. How will continued growth in private label sales affect this market? How can brands appeal to consumers through marketing efforts and product form developments? How are in-store clinics at drug stores and mass merchandise...
Published Date: Apr 2013
Published By: Mintel

Price: $3995
Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012
Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012 Summary GlobalData's "Pharmaceutical & Healthcare Annual Deals Analysis: M&A and Investments Trends - 2012" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on Partnerships, Licensing Agreements, M&As, Equity/Debt Offerings, Private Equity and Venture Financing transactions registered in the pharmaceutical and healthcare industry in 2012. The report presents detail...
Published Date: Mar 2013
Published By: GlobalData

Price: $3500
PharmaSphere: Global Generics Strategy - Key Drivers, Markets and Trends in 2013
PharmaSphere: Global Generics Strategy Key Drivers, Markets and Trends in 2013 Summary GlobalDatas "PharmaSphere: Global Generics Strategy Key Drivers, Markets and Trends in 2013" report, provides strategic analysis of the global generics industry. It discusses key trends, significant M&A deals in 2012, and describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of the top 30 companies into various markets, including the BRIC countries (Brazil, Russia, India, and China), to identify the top players in each market. Throughout the report, GlobalDatas analysts provide you wi...
Published Date: Mar 2013
Published By: GlobalData

Price: $2995
Fatigue Global Clinical Trials Review, H1, 2013
Fatigue Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Fatigue Global Clinical Trials Review, H1, 2013 provides data on the Fatigue clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Fatigue. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Fatigue. This report is built using data and information sourced from proprietary databas...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
Cholangitis Global Clinical Trials Review, H1, 2013
Cholangitis Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Cholangitis Global Clinical Trials Review, H1, 2013" provides data on the Cholangitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholangitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cholangitis. This report is built using data and information sourced fro...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
Vitiligo Global Clinical Trials Review, H1, 2013
Vitiligo Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Vitiligo Global Clinical Trials Review, H1, 2013" provides data on the Vitiligo clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vitiligo. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vitiligo. This report is built using data and information sourced from proprietary d...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
Cholecystitis Global Clinical Trials Review, H1, 2013
Cholecystitis Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Cholecystitis Global Clinical Trials Review, H1, 2013" provides data on the Cholecystitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cholecystitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cholecystitis. This report is built using data and information s...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
Rosacea Global Clinical Trials Review, H1, 2013
Rosacea Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Rosacea Global Clinical Trials Review, H1, 2013" provides data on the Rosacea clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rosacea. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Rosacea. This report is built using data and information sourced from proprietary databases, p...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
Vasculitis Global Clinical Trials Review, H1, 2013
Vasculitis Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Vasculitis Global Clinical Trials Review, H1, 2013" provides data on the Vasculitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Vasculitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Vasculitis. This report is built using data and information sourced from pro...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013
Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013SummaryGlobalData's clinical trial report, Retinal Vein Occlusion Global Clinical Trials Review, H1, 2013" provides data on the Retinal Vein Occlusion clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Retinal Vein Occlusion. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.  The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Retinal Vein Occlusion. This...
Published Date: Mar 2013
Published By: GlobalData

Price: $2500
PharmaPoint: Multiple Sclerosis - US Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis US Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis US Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer&r...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis UK Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis UK Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer&r...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - Spain Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis Spain Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Spain Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) age...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - Japan Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis Japan Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Japan Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: B...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - Italy Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis Italy Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Italy Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: B...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - India Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis India Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: B...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
Gilenya (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Gilenya (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Gilenya (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer&rsq...
Published Date: Mar 2013
Published By: GlobalData

Price: $6995
Rebif (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Rebif (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Rebif (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bayer&r...
Published Date: Mar 2013
Published By: GlobalData

Price: $6995
Tysabri (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Tysabri (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Tysabri (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) agents: Bay...
Published Date: Mar 2013
Published By: GlobalData

Price: $6995
Betaseron/Betaferon (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Betaseron/Betaferon (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Betaseron/Betaferon (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta ...
Published Date: Mar 2013
Published By: GlobalData

Price: $6995
Avonex (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Avonex (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Avonex (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer&rsquo...
Published Date: Mar 2013
Published By: GlobalData

Price: $6995
Copaxone (Multiple Sclerosis) - Forecast and Market Analysis to 2022
Copaxone (Multiple Sclerosis) Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Copaxone (Multiple Sclerosis) Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: Bayer&r...
Published Date: Mar 2013
Published By: GlobalData

Price: $6995
PharmaPoint: Multiple Sclerosis - Germany Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis Germany Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Germany Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agent...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - France Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis France Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis France Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNß) a...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - China Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis China Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis China Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents: B...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - Canada Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis Canada Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Multiple Sclerosis Canada Drug Forecast and Market Analysis to 2022”. Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent on life-long pharmacotherapy with disease-modifying therapies (DMT). The dominance of first-line injectable DMTs, including the interferon beta (IFNB) agents:...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022
PharmaPoint: Multiple Sclerosis - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, "PharmaPoint: Multiple Sclerosis - UK Drug Forecast and Market Analysis to 2022". Multiple sclerosis (MS) is a chronic, inflammatory neurological disorder characterized pathologically by demyelination, axonal transection and neurodegeneration within the central nervous system. With curative therapy still elusive, current disease management is dependent o...
Published Date: Mar 2013
Published By: GlobalData

Price: $4995
Research Report on Chinas Veterinary Active Pharmaceutical Ingredient and Chemical Preparation Industry
The scale of China's veterinary farming industry keeps on increasing with a high-density farming pattern, which will make the prevention of veterinary epidemics in China become increasingly severe. As active pharmaceutical ingredients and chemical preparations are more and more widely used in veterinary farming industry, China's veterinary active pharmaceutical ingredients and chemical preparations industry develops rapidly. Since the breaking up of SARS in 2003 and the bird flu in 2004, China's veterinary active pharmaceutical ingredients and chemical preparations industry has seen increasing prosperity, and the market of veterinary chemicals in China has also seen an average growth rate of over 11%, which is much higher than the average global growth rate of 6%...
Published Date: Mar 2013
Published By: BOABC

Price: $6000
Pharmacy Automation Systems Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
This report provides an in-depth analysis and market forecast for the global pharmacy automation market for the period 2012 – 2018. The report provides details of the several pharmacy automation devices currently available in the market along with the impact of these machines on modern pharmacies in terms of efficiency, reduction in error and speed. The report also highlights the unique connection of pharmacy automation devices with a number of other markets such as the E-prescription market and its role in the growth of pharmacy automation.  The scope of the report includes competitive analysis of major market segments based on end users, technology and of different regional markets such as Europe, North America, Asia-Pa...
Published Date: Mar 2013
Published By: Transparency Market Research

Price: $4595
Research on Chinas FISH Probe (Fluorescent in Situ Hybridization Probe) Industry, 2013-2017
According to Huidian’s market research, the output value of China’s FISH probe market in 2012 was about CNY 20 million to CNY 30 million; with the improvement of people’s living standard and medical conditions in the future, FISH probe products will be more and more used in medical diagnosis. The main brands of China’s FISH probe industry are GP, Abbott, LBP, Zhongsheng Damaidi, BioChina and Zhejiang Orient Gene. In 2012, the FISH probes of GP and Abbott occupied the monopoly position in domestic market, and the market share was about 51% and 32 % respectively, and the market share of LBP was about 13%. At present, the annual sales of China’s clinical diagnostic reagent ma...
Published Date: Mar 2013
Published By: Huidian Research

Price: $2500
Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Market Despite Patent Cliff
Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinsons Disease Treatment will Boost Market Despite Patent Cliff GBI Research, the leading business intelligence provider, has released its latest research “Neurodegenerative Diseases Market to 2018 - New Product Entries in Both Niche and Broader Parkinson’s Disease Treatment will Boost Market Despite Patent Cliff”. A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer’s di...
Published Date: Mar 2013
Published By: GBI Research

Price: $3500
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018
Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. With rise in cancer patients and metabolic diseases like diabetes, there has been a push in growth for ...
Published Date: Mar 2013
Published By: Transparency Market Research

Price: $4595
Global Laboratory Analytical Instrument Market 2012-2016
TechNavio's analysts forecast the Global Laboratory Analytical Instrument market to grow at a CAGR of 5.93 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increased adoption of large molecule analysis instruments by pharmaceutical companies.  The Global Laboratory Analytical Instrument market has also been witnessing the development of instruments with increased features and functionalities. However, the long replacement cycles of laboratory analytical instruments could pose a challenge to the growth of this market. TechNavio's report, Global Laboratory Analytical Instrument Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the...
Published Date: Mar 2013
Published By: Technavio

Price: $3000
Global Nanotechnology Drug Delivery Market 2012-2016
TechNavio's analysts forecast the Global Nanotechnology Drug Delivery market to grow at a CAGR of 73.97 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R&D cost. The Global Nanotechnology Drug Delivery market has also been witnessing an increase in customer support services. However, the increasing safety concerns could pose a challenge to the growth of this market. TechNavio's report, Global Nanotechnology Drug Delivery Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA a...
Published Date: Mar 2013
Published By: Technavio

Price: $2000
Global Kidney Cancer Drugs Market 2012-2016
TechNavio's analysts forecast the Global Kidney Cancer Drugs market to grow at a CAGR of 13.4 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growing demand in developing economies. The Global Kidney Cancer Drugs market has also been witnessing an increase in R&D activities. However, over-dependence of the market on the US could pose a challenge to the growth of this market. TechNavio's report, Global Kidney Cancer Drugs Market 2012-2016, has been prepared based on an in-depth market analysis of the market with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Kidney Cancer Drugs market landscape and its gro...
Published Date: Mar 2013
Published By: Technavio

Price: $2000
Global and China Human Coagulation Factor VIII Industry 2013 Deep Research Report
Summary 2013 Deep Research Report on Global and China Human Coagulation Factor Ⅷ Industry was professional and depth research report on Global and China Human Coagulation Factor Ⅷ industry. This report has firstly introduced Human Coagulation Factor Ⅷ definition classification industry chain etc related information.  Then introduced Human Coagulation Factor Ⅷ manufacturing technology and product specifications, And then summary statistics Global and China major Human Coagulation Factor Ⅷ manufacturers 2010-2016 Human Coagulation Factor Ⅷ capacity production supply demand shortage and Human Coagulation Factor Ⅷ selling price cost profit margin and production value, and also introduced I...
Published Date: Mar 2013
Published By: QYResearch

Price: $2200
China Pharmaceutical Equipment Industry Report, 2012-2015
Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over the years, with industrial sales showing a rapid growth trend. In line with statistics of the China Association for Pharmaceutical Equipment, in 2011 the pharmaceutical equipment industry of China achieved gross industrial output value of RMB15.84 billion, a year-on-year increase of 23.5%; sales of RMB16.1 billion, up 25.2% year-on-year; total profit of RMB1.818 billion, up 19.3% YoY; and gross margin of the industry rose to 11.3%. For now, the leading companies in Chinese pharmaceutical equipment industry...
Published Date: Mar 2013
Published By: Research In China

Price: $2000
Penicillin Markets in China
China's demand for penicillin has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: Mar 2013
Published By: Asia Market Information & Development Company

Price: $2000
Aerosol Markets in China
China's demand for aerosol has grown at a fast pace in the past decade. In the next five years, both production and demand will continue to grow. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2002, 2007 and 2012) and long-term forecasts through 2017 and 2022 are presented. Major producers in China are profiled.
Published Date: Mar 2013
Published By: Asia Market Information & Development Company

Price: $2000
Orphan Drugs Partnering Terms and Agreements
The Orphan Drugs Partnering Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.   Trends in orphan drugs partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Orphan drugs partnering contract documents Top orphan drugs deals by value The OrphanDrugs Partnering Terms and Agreements report provides an understanding and access to the orphan drugs partnering deals and agreements entered into by the worlds leading healthcare companies.   The report provides an understanding and analysis of ho...
Published Date: Feb 2013
Published By: Current Partnering

Price: $1795
Partnering Deals and Alliances with Big Pharma
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits: Detailed partnering activity profiles for each of the top 50 big pharma companies Over 300 charts showing a company’s dealmaking activity since 2005, allowing quick identification potential partners Partnering therapy focus revealed Partnering activity since 2005 – number of deals per year Full listing of partnering deals...
Published Date: Feb 2013
Published By: Current Partnering

Price: $2995
HIV / AIDS - Pipeline Review, H1 2013
HIV / AIDS Pipeline Review, H1 2013 Summary Global Markets Directs, 'HIV / AIDS Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for HIV / AIDS, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV / AIDS. HIV / AIDS Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2500
Parkinson's Disease - Pipeline Review, H1 2013
Parkinson's Disease Pipeline Review, H1 2013 Summary Global Markets Directs, 'Parkinson's Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Parkinson's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Parkinson's Disease. Parkinson's Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentati...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Autoimmune Disorders - Pipeline Review, H1 2013
Autoimmune Disorders - Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Autoimmune Disorders - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Autoimmune Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autoimmune Disorders. Autoimmune Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Stroke - Pipeline Review, H1 2013
Stroke - Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Stroke - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Stroke. Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Ce...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Myocardial Infarction - Pipeline Review, H1 2013
Myocardial Infarction - Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Myocardial Infarction - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myocardial Infarction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myocardial Infarction. Myocardial Infarction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Spinal Cord Injury - Pipeline Review, H1 2013
Spinal Cord Injury - Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Spinal Cord Injury - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Spinal Cord Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Spinal Cord Injury. Spinal Cord Injury - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together ...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013
Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections. Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investo...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013
Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections. Cytomegalovirus (HHV-5) Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from c...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Inflammatory Pain - Pipeline Review, H1 2013
Inflammatory Pain Pipeline Review, H1 2013 Summary Global Markets Directs, 'Inflammatory Pain Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Pain. Inflammatory Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and fe...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Fungal Infections - Pipeline Review, H1 2013
Fungal Infections Pipeline Review, H1 2013 Summary Global Markets Directs, 'Fungal Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fungal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fungal Infections. Fungal Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and fe...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Arthritis - Pipeline Review, H1 2013
Arthritis Pipeline Review, H1 2013 Summary Global Markets Directs, 'Arthritis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Arthritis. Arthritis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/unive...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013
Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review, H1 2013 Summary Global Markets Directs, 'Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Plaque Psoriasis (Psoriasis Vulgaris). Plaque Psoriasis (Psoriasis Vulgaris) Pipeline Review, Half Year is built using data and information sourced from Global Markets Di...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2013
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review, H1 2013 Summary Global Markets Directs, 'Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). Radiation Toxicity ...
Published Date: Feb 2013
Published By: Global Markets Direct

Price: $2000
Prev 1 2 3 4 5 6 7 8 9 10 Next